Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prokidney (PROK) EBITDA (2022 - 2025)

Prokidney (PROK) has disclosed EBITDA for 4 consecutive years, with -$45.4 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 12.02% to -$45.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$165.0 million through Dec 2025, up 10.16% year-over-year, with the annual reading at -$165.0 million for FY2025, 10.16% up from the prior year.
  • EBITDA for Q4 2025 was -$45.4 million at Prokidney, down from -$38.5 million in the prior quarter.
  • The five-year high for EBITDA was -$20.7 million in Q2 2022, with the low at -$66.5 million in Q1 2022.
  • Average EBITDA over 4 years is -$40.8 million, with a median of -$40.5 million recorded in 2023.
  • The sharpest move saw EBITDA surged 38.5% in 2023, then crashed 113.02% in 2024.
  • Over 4 years, EBITDA stood at -$30.2 million in 2022, then grew by 19.93% to -$24.2 million in 2023, then tumbled by 113.02% to -$51.6 million in 2024, then grew by 12.02% to -$45.4 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$45.4 million, -$38.5 million, and -$39.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.